Tamás Lázár graduated with a master’s degree in medical biotechnology from the Semmelweis Medical University and Catholic University of Budapest. Until 2016, he worked at the Institute of Enzymology in Budapest as a junior researcher. In 2020, he completed his PhD in bioengineering at VUB with a focus on protein bioinformatics, disordered proteins and biocuration for databases in Peter Tompa’s lab. In 2019 and 2023, he concluded two Marie Curie short-term fellowships in Buenos Aires at Leloir Institute and IIB-UNSAM. Currently he's a postdoctoral VLAIO innovation mandatee at VIB in Brussels, and focuses on drug discovery for aggregation-prone ALS-driver proteins. He has authored 25 publications with over 1,000 cumulative citations.

About VIB
VIB is an entrepreneurial non-profit research institute with a clear focus on groundbreaking strategic basic research in life sciences. It operates in close partnership with the five universities in Flanders. Currently, VIB has 10 research centers located on 6 campuses. VIB’s mission is to pursue original and strategic basic research, push the frontiers of knowledge in the life sciences, with the overarching goal to translate the gained insights and scientific breakthroughs into real-world applications, which leads to both societal and economic benefits. VIB does this by nurturing exceptional talent, creativity, and state-of-the-art technology to uncover the uncharted territory of human knowledge.

Marijne Vandebergh graduated with a master’s degree in Biomedical Sciences from the KU Leuven in 2017, after which she pursued a PhD degree at the Laboratory for Neuroimmunology, KU Leuven. In her doctoral studies, Marijne investigated the role of the environment and genetics on the susceptibility and clinical heterogeneity of the autoimmune disease multiple sclerosis. In 2019, Marijne conducted a research stay at the University of Tasmania in Hobart, Australia and completed her PhD at KU Leuven in 2022. Currently, she is a second-year postdoctoral researcher at the VIB-UAntwerp Center for Molecular Neurology in the Rademakers lab, focusing on genetic modifiers in the neurological disorder frontotemporal lobar degeneration (FTLD). 

About VIB
VIB is an entrepreneurial non-profit research institute with a clear focus on groundbreaking strategic basic research in life sciences. It operates in close partnership with the five universities in Flanders. Currently, VIB has 10 research centers located on 6 campuses. VIB’s mission is to pursue original and strategic basic research, push the frontiers of knowledge in the life sciences, with the overarching goal to translate the gained insights and scientific breakthroughs into real-world applications, which leads to both societal and economic benefits. VIB does this by nurturing exceptional talent, creativity, and state-of-the-art technology to uncover the uncharted territory of human knowledge

Yvonne joined iTeos in 2020 as Vice President of Research & Development. With more than 20 years of international experience in oncology drug discovery and development, she has taken lead candidates from early stage research into clinical trials. Immediately prior to iTeos , she served as CSO and board member in Complix, a company developing novel biologics. She has also lead R&D activities in UK based biotech companies including Immunocore and Biovex. Yvonne holds a PhD from the University of Wales, College of Medicine.

About iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company headquartered in Watertown, MA, with a research center in Gosselies, Belgium. Our teams work across departments, companies, and borders with a common purpose: pioneering the discovery and development of a new generation of immunotherapies for people living with cancer. We believe collaboration is critical to achieving our mission. Our team builds upon individual talents and expertise, working in synergy to bring out the best in each other—with the best people and technologies.